Gilead Sciences, Inc.

- Gilead does not expect sizable M&A or meaningful new fundraising through debt or equity in the near term. - The company has about $5 billion in cash and leverage back to pre-Immunomedics deal levels. - Gilead plans to continue ordinary course licensing deals and smaller transactions rather than large M&A. - They intend to remain disciplined with capital allocation, investing in pipeline and operational priorities. - The company emphasized flexibility in balance sheet management but highlighted no plans for sizable M&A or fundraising shortly. - Overall, Gilead is focused on organic growth and pipeline execution with current resources.

- Gilead plans to double its manufacturing capacity for cell therapy, as highlighted at the recent Kite analyst event. - They aim to expand into new indications and disease areas with next-generation products in cell therapy. - Gilead will invest in launching seladelpar following regulatory approval, including incremental investments to support the product launch and R&D efforts. - Capital allocation remains disciplined, with a focus on ordinary course M&A and licensing deals rather than sizable acquisitions in the near term. - The CymaBay acquisition includes plans for a launch in the second half of 2024, with modest 2024 revenue contribution and further investments anticipated to manage launch and R&D within the existing expense framework. - Gilead emphasizes disciplined operating expense management and intends to continue operational margin improvement driven by revenue growth and expense control.

- Gilead expects total product sales in 2024 (excluding Veklury) to grow 4%-6% year over year, in the range of $25.8 to $26.2 billion. - HIV product sales are expected to grow approximately 4% in 2024 despite headwinds from Medicare Part D redesign impacting HIV franchise growth in 2025. - Oncology sales are showing strong momentum with Trodelvy and cell therapies, supporting continued growth. Trodelvy sales exceeded $1 billion annually and have multiple Phase 3 trials underway for new indications. - The newly acquired seladelpar (from CymaBay) is expected to contribute modestly to sales in 2024 with more meaningful growth anticipated in 2025 and beyond. - Gilead plans to expand cell therapy indications, double manufacturing capacity, and launch next-generation products, targeting growth beyond 2025. - Overall, Gilead expects total business growth in 2025 despite some flat HIV sales due to Part D impact, driven by other segments building momentum into 2026 and later.

- 2024 diluted EPS guidance is $3.45 to $3.85, updated due to CymaBay acquisition charges; excluding charges, EPS is within early February guidance range. - The CymaBay transaction is expected to be dilutive to EPS in 2024 but breakeven in 2025, with significant accretion thereafter. - Operating expenses continue disciplined management, expecting mid-single-digit percentage decline in operating expenses versus 2023 (excluding CymaBay expenses). - Non-GAAP gross margin guidance remains unchanged, with product gross margins expected to grow. - R&D spending expected to grow at the higher end of prior low-to-mid single-digit growth due to CymaBay-related incremental expenses. - SG&A modestly higher due to CymaBay but managed within operating expense guidance. - Operating margins expected to improve over time through top-line growth and disciplined expense management. - HIV franchise growth expected to be flat in 2025 due to Medicare Part D redesign impact; overall business expected to grow despite this headwind. - More detailed 2025 guidance to be provided early next year.

The provided pages from Gilead Sciences' Q1 2024 earnings call transcript do not explicitly mention the current or expected orderbook or pending orders details. However, relevant points related to sales and business outlook include: - Total product sales excluding Veklury grew 6% YoY to $6.1 billion in Q1 2024. - HIV product sales grew 4% YoY, with continued demand and pricing strength. - Oncology product sales were up 18% YoY, driven by Trodelvy and cell therapies. - Liver disease sales increased 9% YoY, driven by HCV, HBV, and HDV products. - Veklury sales declined 3% YoY due to lower COVID-19 hospitalizations. - Seladelpar launch expected in 2024 with modest sales contribution; more meaningful growth anticipated in 2025 and beyond. - Management confident in returning to growth in the second half of 2024, especially in cell therapy. - No specific details on orderbook or pending orders were disclosed.